Bispecific Antibodies

Bispecific antibodies
#AbbVie #Bispecific Antibodies #Cancer research #CHMP #EMA #Genmab #Haematology #Oncology

Bispecific antibody a “promising treatment option” for DLBCL

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines… Read More

#News #Regulatory

Multiple myeloma
#Bispecific Antibodies #Cancer research #CHMP #EMA #Janssen #Myeloma #Oncology

CHMP recommendation for bispecific antibody talquetamab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The drug has received a positive opinion for use as a monotherapy for the treatment of adult patients with… Read More

#News #Regulatory

Cancer immuno-oncology
#AI / data analytics / healthtech / informatics #Bispecific Antibodies #Bispecific therapeutics #Cambridge Healthtech Institute #Cancer immunotherapy #Events #Immuno-oncology #Next generation sequencing

Immuno-Oncology Summit Europe 2023: Programme highlights 

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. DDW’s Megan Thomas shares highlights from the event programmes.   Programmes   This year’s summit was made up of conference programmes, which included: Modulating the Tumour Microenvironment; Next-Generation Cell-Based Immunotherapies; Bispecific… Read More

#Cancer Research #Exclusive Content #Opinion

B-cells in multiple myeloma
#Bispecific Antibodies #Cancer research #Immunotherapy #IOME Bio

IOME Bio’s science represents breakthrough in cancer research 

IOME Bio, a seed stage biotechnology company focused on overcoming tumour resistance to immune checkpoint inhibition, has published its foundational research by founders Dr Arlene Sharpe and Dr Dennis Kasper in Nature.   By providing evidence of its therapeutic relevance, it reveals insights into the importance… Read More

#News

Antibodies attacking cancer cell
#Bispecific Antibodies #Cancer research #Cancer treatment #Mergers and acquisitions #Monoclonal antibodies #Oncology

Jazz acquires rights to HER2-targeted bispecific antibody

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More

#Cancer Research #News

Laboratory research
#Antibodies #Antibody Fragments #Bispecific Antibodies #Fc-Fusion proteins

App note: recombinant antibody formats, expressions & applications

Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents. There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies. Compared to monoclonal antibodies produced using traditional hybridoma techniques,… Read More

#News